+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Canada Breast Cancer Therapeutics Market 2019-2025

  • PDF Icon


  • February 2020
  • Region: Canada
  • Orion Market Research Private Limited
  • ID: 5116810
Canada Breast Cancer Therapeutics Market Size, Share & Trends Analysis Report by Therapy (Chemotherapy, Hormone Therapy, Targeted Therapy, Radiation Therapy, and others) and Forecast 2019-2025.

Canada breast cancer therapeutics market is estimated to grow significantly at a CAGR of around 8.8% during the forecast period. The factors that enable the growth of the market include the prevalence of breast cancer and the initiative by the government and private organizations. Breast cancer is the second leading cause of mortality in Canada. The incidence rate of breast cancer in Canada slightly increases with the increase in years. According to the Canadian Cancer Society about 26,300 women diagnosed with breast cancer in 2017. This accounts for 25% of all new cancer cases in women. The most common age for breast cancer in Canadian women is 50-70. The mortality rates from breast cancer are decreased due to early diagnosis and treatment options. According to the Canadian Cancer society, the mortality rate per 100,000 was 23.2 in 2017.

Canada breast cancer therapeutics market is segmented on the basis of therapy. The therapy segment is further classified into chemotherapy, hormone therapy, targeted therapy, radiation therapy and others (surgery). Among all therapies, the chemotherapy market held the largest market share in the Canada breast cancer therapeutics market. Chemotherapy is most used when cancer in the lymph nodes and irrespective of tumor size or menopausal status. Along with that it is used for the treatment of breast cancer in premenopausal women and referred for those women who diagnosed with early stage breast cancer for hormone receptor negative and HER2 positive cancer. The types of chemotherapy include adjuvant chemotherapy and neoadjuvant chemotherapy. The adjuvant chemotherapy is used to destroy cancer cells that have been spread and not seen by the imaging tests. This method helps in reducing the cancer cells that form a new tumor in the other place of the body. Adjuvant chemotherapy reduces the risk of breast cancer coming back. Neoadjuvant chemotherapy can be used to reduce the size of the tumor, so it can be removed with less widespread surgery.

The companies which are contributing to the growth of the Canada breast cancer therapeutics market include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Halozyme, Inc., Johnson & Johnson Services Inc., Merck & Co., Inc., Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of the Canada breast cancer therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

Market Segmentation:

1. Canada breast cancer Therapeutics Market Research and Analysis by Therapy

The Report Covers:
  • Comprehensive Research Methodology of the Canada breast cancer therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Canada breast cancer therapeutics market.
  • Insights about market determinants which are stimulating the Canada breast cancer therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Co.
  • Celldex Therapeutics, Inc.
  • Eli Lilly and Co.
  • Halozyme, Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • MacroGenics, Inc.
  • Pfizer Inc.